Welcome to our dedicated page for BioCryst Pharmaceuticals news (Ticker: $BCRX), a resource for investors and traders seeking the latest updates and insights on BioCryst Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioCryst Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioCryst Pharmaceuticals's position in the market.
BioCryst Pharmaceuticals (Nasdaq: BCRX) will present new data on ORLADEYO® (berotralstat), an oral, once-daily treatment for hereditary angioedema (HAE), at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Valencia, Spain from May 31 to June 3, 2024. The company will present two abstracts: one on adverse health outcomes and perspectives of attenuated androgen use, and another on the effectiveness and safety of berotralstat in patients with HAE with normal C1 inhibitor. These presentations are scheduled for May 31 and June 2, 2024.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that COFEPRIS in Mexico approved ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The drug is now approved in four countries in the pan-Latin America region. BioCryst collaborates with Pint Pharma to bring the therapy to HAE patients in need.
BioCryst Pharmaceuticals, Inc. presented new real-world evidence demonstrating significant reductions in healthcare resource utilization (HRU) among patients with hereditary angioedema (HAE) in the United States after initiating ORLADEYO® (berotralstat) treatment. The study, presented at the 2024 ISPOR conference, highlighted reduced all-cause hospitalizations and angioedema-related hospitalizations, showcasing the cost-effectiveness and collective benefit of ORLADEYO therapy for patients and payers.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) will be presenting at various upcoming investor conferences in May and June 2024. The presentations will take place in New York and Las Vegas, offering investors insights into the company's latest developments and future prospects.
BioCryst Pharmaceuticals, Inc. reported a 30% y-o-y growth in ORLADEYO net revenue to $88.9 million in Q1 2024. The full-year 2024 ORLADEYO revenue guidance was adjusted to $390-$400 million, Pipeline programs advancing on schedule. Financial results showed total revenues of $92.8 million in Q1 2024, with an operating loss of $14.5 million. The company expects full-year 2024 operating expenses to be between $365 million and $375 million. BioCryst is confident in achieving a full-year operating profit in 2024 and positive cash flow in the second half of 2025.
BioCryst Pharmaceuticals, Inc. announced the granting of stock options and restricted stock units to 10 newly-hired employees as inducements for joining the company. The options have an exercise price of $4.13 per share, vesting in four annual installments over 10 years, subject to continued service.
